A detailed history of Mercer Global Advisors Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Mercer Global Advisors Inc holds 11,393 shares of SUPN stock, worth $364,576. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,393
Previous 12,113 5.94%
Holding current value
$364,576
Previous $413,000 26.39%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$25.99 - $33.85 $18,712 - $24,372
-720 Reduced 5.94%
11,393 $304,000
Q1 2024

May 15, 2024

BUY
$27.11 - $35.17 $21,986 - $28,522
811 Added 7.18%
12,113 $413,000
Q4 2023

Feb 14, 2024

SELL
$22.72 - $29.68 $1,045 - $1,365
-46 Reduced 0.41%
11,302 $327,000
Q3 2023

Nov 13, 2023

SELL
$27.57 - $32.91 $3,749 - $4,475
-136 Reduced 1.18%
11,348 $313,000
Q2 2023

Aug 14, 2023

BUY
$29.91 - $38.73 $31,943 - $41,363
1,068 Added 10.25%
11,484 $345,000
Q1 2023

May 15, 2023

BUY
$34.93 - $42.03 $9,186 - $11,053
263 Added 2.59%
10,416 $377,000
Q4 2022

Feb 08, 2023

SELL
$31.09 - $37.88 $79,932 - $97,389
-2,571 Reduced 20.21%
10,153 $362,000
Q3 2022

Nov 15, 2022

BUY
$28.79 - $35.41 $14,682 - $18,059
510 Added 4.18%
12,724 $431,000
Q2 2022

Aug 10, 2022

BUY
$25.33 - $34.25 $810 - $1,096
32 Added 0.26%
12,214 $353,000
Q1 2022

May 10, 2022

BUY
$28.51 - $32.9 $66,770 - $77,051
2,342 Added 23.8%
12,182 $394,000
Q4 2021

Feb 04, 2022

BUY
$26.37 - $34.22 $8,306 - $10,779
315 Added 3.31%
9,840 $287,000
Q3 2021

Nov 10, 2021

SELL
$23.54 - $31.39 $7,344 - $9,793
-312 Reduced 3.17%
9,525 $254,000
Q2 2021

Aug 10, 2021

BUY
$26.72 - $33.19 $262,844 - $326,490
9,837 New
9,837 $303,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.71B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Mercer Global Advisors Inc Portfolio

Follow Mercer Global Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.